Jump to ContentJump to Main Navigation
Human Rights and the WTOThe Case of Patents and Access to Medicines$
Users without a subscription are not able to see the full content.

Holger Hestermeyer

Print publication date: 2008

Print ISBN-13: 9780199552177

Published to Oxford Scholarship Online: January 2009

DOI: 10.1093/acprof:oso/9780199552177.001.0001

Show Summary Details
Page of

PRINTED FROM OXFORD SCHOLARSHIP ONLINE (www.oxfordscholarship.com). (c) Copyright Oxford University Press, 2020. All Rights Reserved. An individual user may print out a PDF of a single chapter of a monograph in OSO for personal use. date: 24 February 2020

Background of the Debate

Background of the Debate

Chapter:
(p.1) 1 Background of the Debate
Source:
Human Rights and the WTO
Author(s):

Holger Hestermeyer

Publisher:
Oxford University Press
DOI:10.1093/acprof:oso/9780199552177.003.0001

This chapter discusses the facts that called attention to the conflict between the TRIPS Agreement and access to medicine. The public discussion was initially triggered by the pricing decision of the patent holder of the first AIDS medicine AZT. It took on global proportions when the pharmaceutical industry sued the South African government that wanted to impose compulsory licences for patents on pharmaceuticals to provide its population with cheap AIDS medication. The chapter also recounts the events surrounding the anthrax attacks in the United States, when the Canadian and US governments threatened to break Bayer's patent on Cipro.

Keywords:   TRIPS Agreement, access to medicine, international patents, AZT, South Africa, AIDS, Anthrax, Cipro

Oxford Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs , and if you can't find the answer there, please contact us .